Debiopharm

Updated on Dec 18, 2023

Edit

Comment

Type Société Anonyme Area served Worldwide Headquarters Lausanne Number of employees 350		Industry biopharmaceutical Founded 1979 Motto We develop for patients

Founder Dr Rolland-Yves Mauvernay Key people Rolland-Yves Mauvernay (Co-President)Thierry Mauvernay (Co-President)Bertrand Ducrey (CEO Debiopharm International SA)Cédric Sager (CEO Debiopharm Research & Manufacturing SA)Valérie Calvayrac (CEO Debiopharm Investment SA) Products Triptorelinoxaliplatin Profiles LinkedIn

Debiopharm Group (Debiopharm) is a family-owned biopharmaceutical group of companies headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay.

The group works through its subsidiaries:

Debiopharm International SA, which in-licenses product candidates or technologies, develops them, and then licenses them to third parties for commercialization;

Debiopharm Research and Manufacturing SA, which provides contract manufacturing and contract research services to Debiopharm;

Debiopharm Investment SA, which manages the group's money and invests in real estate and in other companies; and

Debiopharm Diagnostics SA, which invests in diagnostics companies.

As of 2010 two drugs had reached the market through its efforts: oxaliplatin for the treatment of cancer, and depot formulations of triptorelin, a gonadotropin-releasing hormone agonist that is approved to treat advanced prostate cancer.

References

Debiopharm Wikipedia

(Text) CC BY-SA